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Abstract
Introduction. The increasing worldwide prevalence of lifestyle diseases, including cardiovascular disorders, makes pre-
ventive measures more and more important. The identification of risk factors for cardiovascular events (CVEs) allows 
for determination of people requiring implementation of effective primary prevention.
The aim of the present study was to assess the prevalence of metabolic syndrome (MS) in the urban population of 
Poland. The second aim was to assess which of the MS definition increased the risk of development of CVEs.
Material and methods. 798 people were included in the prospective study. In all study participants anthropometric 
measurements, blood pressure, biochemical tests and standardized questionnaire history of actual physical condition 
as well as lifestyle and family history of cardiovascular diseases and diabetes were examined.
Results. During the baseline study, MS according to World Health Organization criteria was diagnosed in 13.6% people. 
When considering third report of the National Cholesterol Education Program — Adult Treatment Panel (NCEP-ATP III) 
criteria, the prevalence of the MS raised up to 32.7% of the participants. According to the International Diabetes Fe-
deration (IDF) criteria, 43.7% of the people were diagnosed with MS. In the follow-up study, the prevalence of nonfatal 
cardiovascular events was 5.8%. Male gender, body mass index ≥ 25 kg/m2, abdominal obesity (measured by waist-to-
-hip ratio), glucose 120’ oral glucose tolerance test, high-density lipoprotein cholesterol and MS (NCEP and IDF criteria) 
were significantly and independently related to myocardial infarction (MI) and/or stroke.
Conclusions. Taking into account potential risk factors of CVEs, the most valuable in the identification of people with 
increased risk of developing MI and/or stroke was the MS definition according to NCEP-ATP III and IDF.
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Introduction
The increasing worldwide prevalence of lifestyle diseases, 
including cardiovascular disorders, makes preventive mea-
sures more and more important. The identification of risk 
factors for myocardial infarction (MI) and stroke allow for 
determination of people requiring implementation of effec-
tive primary prevention. This will definitely help to reduce 
the incidence and morbidity due to cardiovascular diseases.
In Poland cardiovascular diseases are still the leading 
cause of death, including a significant percentage of pre-
mature deaths. The Polish Forum for Prevention stresses 
the need to implement an effective primary prevention 
strategy at the level of the general population [1]. Metabolic 
syndrome (MS) is much more common among patients with 
cardiovascular disease, including coronary artery disease, 
hypertension and ischemic stroke [2–6]. Conversely, indi-
viduals who meet the criteria for the diagnosis of MS have 
an increased risk of developing cardiovascular diseases. 
A meta-analysis of 37 studies that used the definition by 
World Health Organization (WHO) and third report of the 
National Cholesterol Education Program — Adult Treatment 
Panel (NCEP-ATP III) found that the presence of MS incre-
ases the risk of cardiovascular events (CVEs) and death 
1.78 times in total [7].
The aim of the study was to assess the prevalence of 
MS in the urban population of Poland and to assess which 
of the MS criteria (WHO, NCEP-ATP III or International Dia-
betes Federation [IDF]) correlate with an increased risk of 
nonfatal CVEs development.
Material and methods
The present analysis is based on the data gathered within 
the framework of the Project ordered by the Ministry of 
Health entitled: “Primary and secondary prevention and 
its impact on epidemiological and economic indicator in 
type 1 and type 2 diabetes in the Polish population” in the 
1998–2000, and then extended to the follow-up study 
conducted in 2007–2009. Contractor for the project was 
the Department of Endocrinology Jagiellonian Universi-
ty Collegium Medicum (UJCM). The study protocol was 
approved by the Bioethics Committee of the Jagiellonian 
University in Krakow.
A random sample of 2838 participants was recruited 
at the baseline survey (response ratio of 47%) from the 
residents of the district Podgórze in Krakow. After the 
mean of 8.8 (standard deviation [SD] = 1.76) years the 
subjects who in the baseline study did not have diagnosed 
diabetes or did not report a history of CVEs were included 
in the present study (Figure 1). The final sample comprised 
798 participants.
In both, the baseline and the follow-up study, partici-
pants fulfilled a structured questionnaire and were invited 
at clinical investigation. The physical investigation included 
measurements of blood pressure, height, weight, waist and 
hip circumference. Body mass index (BMI — m/kg2) and 
waist-to-hip ratio (WHR) were calculated according to the 
standard protocol. Biochemical examination included fast-
ing glucose (mmol/l) and insulin (µU/ml), total cholesterol, 
high-density lipoprotein (HDL)-cholesterol and triglycerides. 
For the measurement of fasting plasma glucose and fasting 
plasma insulin a blood sample was taken after an overnight 
fast. In people not treated due to diabetes mellitus type 
2 (DM2) oral glucose tolerance test with testing of blood 
glucose and insulin at 120 min after administration of 
75 g glucose was performed. Information on lifestyle and 
Figure 1. Characteristics of groups in baseline and follow-up stu-
dies; *2 people were excluded, because of the lack of anthropo-
metric measurements and/or biochemical results in follow-up 
study; CVEs — cardiovascular events; n — numbers
263www.journals.viamedica.pl/folia_cardiologica
Renata Turek-Jabrocka et al., Metabolic syndrome and risk of cardiovascular events
healthy behaviors, the current state of health and family 
history of CVEs and DM2 were obtained by the structured 
questionnaire.
The data obtained in the follow-up study were then 
compared with the data obtained in the baseline study. 
In order to identify people with MS, three MS definitions 
were used — the WHO of the 1999, the NCEP-ATP III of the 
2001 and IDF of the 2005. Nonfatal CVEs defined as MI 
or stroke were identified on the basis of the answer to the 
question “Have cardiovascular disease like myocardial 
infarction or stroke ever been diagnosed by a doctor?“ 
included in the questionnaire.
Statistics
Difference in baseline demographic and clinical charac-
teristics were assessed by CVEs status with the standard 
methods: c2 test for categorical variables, and t-Student or 
Mann-Whitney tests for continuous variables.
Incidence rates of CVEs were calculated dividing num-
ber of events by person-time at risk while the follow-up 
time was the number of months between the baseline 
visit and either the first event or last contact. Multivariate 
proportional hazard regression analysis was applied to 
model the relationship between MS status assessed by 
different definitions and CVEs, adjusted to age, gender, and 
smoking habit. The proportional hazards assumption was 
tested by inspecting Schoenfeld residuals [8] and found 
to be satisfactory.
Statistical analysis was performed using Statistica 10PL 
and SAS for Windows ver. 9.4 (SAS Institute, Cary, NC). A p va- 
lue < 0.05 was considered as statistically significant [8].
Results
During the baseline study MS by WHO criteria from 1999 
was diagnosed in 13.6% of patients, according to the 
NCEP-ATP III 2001 in 32.7% and by the IDF from 2005 
in 43.7% of the study group. In the follow-up study MS by 
WHO was diagnosed in 15.9%, according to the NCEP-ATP III 
in 34.6% and by IDF in 49.2% of the study group. In the 
study group of 798 people, after an average observation 
period of 8.8 (± 1.75) years, nonfatal CVEs were observed 
in 5.8% of the patients (n = 46). Anthropometric and me-
tabolic parameters of the baseline study in patients with 
and without CVEs history identified in the follow-up study 
are presented in Table 1.
A similar analysis was performed after taking into ac-
count gender. Women with CVEs history were older, had 
higher waist-to-hip ratio, and MS by NCEP and IDF was rec-
ognized among them more often. Women after CVEs show 
higher systolic (p = 0.003) and diastolic blood pressure 
(p = 0.002), higher levels of LDL (p = 0.016) and lower HDL-
-cholesterol levels compared with the group of women with-
out CVEs (p = 0.004). All these differences were statistically 
significant. In the group of men with CVEs no statistically 
significant differences in anthropometric and metabolic 
parameters in comparison with the group of men without 
CVEs was observed. Men with CVEs were significantly more 
frequently treated for hypercholesterolemia (p = 0.01) and 
hypertension (p < 0.003) compared with the group of men 
without completed CVEs. In women, these differences were 
not observed. In both women and men, there was a higher 
incidence of CVEs in subjects with previously identified 
MS compared with those without metabolic disorders. 
This difference was statistically significant (in women, 
p < 0.001; in men, p = 0.042). For both, men and women, 
the cumulative hazard of cardiovascular events related to 
MS by WHO, NCEP and IDF is presented in (Figures 2–4).
Results of the Cox regression analysis showed that the 
risk of CVEs was 2-fold higher in men compared with women 
and increased with age. These associations were statisti-
cally significant (Table 2). In the multivariate regression 
model, after adjustment for age and sex, it was found that 
the potential factors that increased the risk of CVEs in the 
study group were: BMI ≥ 25 kg/m2, abdominal obesity as 
curtained by waist-to-hip ratio, glucose in 120’ OGTT and 
HDL cholesterol. These associations were statistically signi-
ficant (Table 3). The greatest risk of CVEs were observed for 
visceral obesity diagnosed on the basis of WHR (HR 4.44, 
p = 0.04). For diagnosis of MS according to the NCEP and 
IDF criteria it was found that individuals with the syndrome 
was approximately 2.5 times more likely to develop CVE 
that individuals without the syndrome. In both cases these 
associations were statistically significant (Table 4).
Discussion
For primary prevention of cardiovascular diseases it is 
necessary to search for risk factors for these diseases in 
the population. Many countries developed risk cards using 
simple parameters such as gender, age, total cholesterol 
and HDL cholesterol in the blood serum, blood pressure, 
history of smoking and type 2 diabetes. These cards es-
timate 5- and 10-year risk of the cardiovascular diseases 
development [9–11]. In the present study attempts were 
undertaken to assess which CVEs risk factors are valu-
able and at the same time simple indicators were sought, 
which would allow for identification of persons who need 
primary prevention of cardiovascular diseases in the Po-
lish population.
In the study group, taking into account the three 
definitions of MS, the percentage of people with MS is 
much higher compared with other epidemiological studies 
[12–16]. It should be emphasized that the study group 
included a significant proportion of people with overweight 
and obesity, and that the average age was higher compared 
with most large population studies. Many studies have 
shown that MS is more common in people with obesity and 
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Figure 2. Cumulative hazard of cardiovascular events related to 
metabolic syndrome (MS) by World Health Organization (WHO), 
adjusted to age and sex
Figure 3. Cumulative hazard of cardiovascular events related to 
metabolic syndrome (MS) by National Cholesterol Education Pro-
gram (NCEP), adjusted to age and sex
Table 1. Anthropometric and metabolic parameters from the baseline study by volunteers without and with cardiovascular events exami-
ned during the follow-up study*
Anthropometric and metabolic parameters from 
the baseline study
The follow-up study p**
Without cardiovascular events After cardiovascular events
Number [%] n = 752 (94.2%) n = 46 (5.8%)
Age, years 50 (13) 53 (10) 0.011
BMI [kg/m2] 27 (5.6) 28.8 (4.0) 0.011
Fasting glucose [mmol/l] 5.5 (0.9) 5.7 (0.8) 0.16
Glucose 120’ OGTT [mmol/l] 6.1 (2.2) 6.4 (2.1) 0.06
Fasting insulin [μIU/ml] 8.2 (8.4) 9.6 (9.5) 0.11
Insulin 120’ OGTT [IU/ml] 24.0 (47.9) 51.4 (62.2) 0,17
HOMA-IR 2.02(2.16) 2.36(2.63) 0,10
Diastolic BP [mm Hg] 80.9 (10.2) 85.7 (12.2) < 0.001
Systolic BP [mm Hg] 124.4 (10.2) 135.4 (24.7) < 0.001
Total cholesterol [mmol/l] 6.1 (1.1) 6.4 (1.2) 0.053
HDL [mmol/l] 1.3 (0.3) 1.1 (0.3) < 0,001
LDL [mmol/l] 4.0 (1.0) 4.4 (1.2) < 0.001
Triglycerides [mmol/l] 1.41 (1.13) 1.81 (1.12) 0.06
Volunteers during hypercholesterolemia treatment 118 (18.6%) 14 (35.9%) 0.02
Volunteers during hypertension treatment 191 (28.4%) 22 (51.6%) 0.006
Smoking Non-smoker 352 (46.8%) 16 (34.8%)
Smoker 196 (26.0%) 10 (21.7%) 0.05
Former smoker 204 (27.2%) 20 (43.5%)
Positive family history of heart disease 512 (68%) 35 (76%) 0.26
Positive family history of diabetes 196 (26.1%) 11 (23.9%) 0.75
*Data are presented as mean ± standard deviation; **a p value of < 0.05 is considered statistically significant; BMI — body mass index; OGTT — oral glucose tolerance test; HOMA-IR — homeostatic model 
assessment — insulin resistance; BP — blood pressure; HDL — high-density lipoprotein; LDL — low-density lipoprotein
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Figure 4. Cumulative hazard of cardiovascular events related to 
metabolic syndrome (MS) by International Diabetes Federation 
(IDF), adjusted to age and sex
Table 2. The risk of cardiovascular events related to age and gen-
der estimated by univariate Cox regression analysis in the whole 
study group
The risk of cardiovascular events
HR 95% CI p*
Age 1.03 1.003–1.07 0.03
Sex (male vs. female) 2.10 1.17–3.78 0.01
*A p value of < 0.05 is considered statistically significant; CI — confidence interval; HR — hazard 
ratio
Table 3. The risk of cardiovascular events associated with individual components of metabolic syndromes, standardized for age and gen-
der. Each factor was estimated in a separate model
Variables (baseline study) The risk of cardiovascular events
HR 95% CI p*
BMI < 25 [kg/m2]
25 ≤ BMI < 30 [kg/m2]
BMI ≥ 30 [kg/m2]
1.0
2.73
2.81
1.03–7.22
1.01–7.84
0.043
0.048
WHR female > 0.85, male > 0.9 4.48 1.07–18.82 0.041
Waist circumference female > 88; male > 102 cm 1.20 0.63–2.30 0.58
Waist circumference female ≥ 80, male ≥ 94 cm 1.67 0.81–3.45 0.17
Fasting glucose 1.28 0.79–2.09 0.32
Glucose 120’ OGTT 1.20 1.01–1.43 0.034
Fasting hyperinsulinemia** 1.33 0.73–2.44 0.35
Hyperinsulinemia 120’ OGTT*** 1.47 0.82–2.65 0.20
Insulin resistance**** 1.40 0.77–2.53 0.27
HDL 0.16 0.05–0.49 0.001
Triglycerides 1.06 0.82–1.36 0.066
*A p value of < 0.05 is considered statistically significant; **fasting hyperinsulinemia — fasting insulin > 11.7 µIU/ml; ***hyperinsulinemia 120’ OGTT — insulin in 120 min OGTT > 57.0 µIU/ml; ****insulin 
resistance — HOMA-IR > 2.78: HR — hazard ratio; CI — confidence interval; BMI — body mass index; WHR — waist-to-hip ratio; OGTT — oral glucose tolerance test; HDL — high-density lipoprotein; HOMA-IR — 
homeostatic model assessment — insulin resistance
in the elderly [17]. In a study of only patients with obesity, 
MS by NCEP-ATP III was found in 60.6% of patients. In the 
cited work the average BMI was 42.3 (± 7.4) kg/m2 [18].
In our work, nonfatal CVEs were observed in 5.8% of 
patients during the 9-year follow-up. In a Danish prospective 
study, in which the median follow-up time was 9.4 years 
and the average age of the respondents was 51 years, at 
the end of the follow-up, CVEs were observed in 9.4% of 
patients [19]. According to a Swedish prospective study, 
among more than 5 thousand people without DM at base-
line, MI and/or stroke was observed in 6.9% of the study 
population during the 11 years follow-up [20]. On the other 
hand, in a prospective study of the Framingham Offspring 
Study, CVEs occurred in 6.5% of the study population, dur-
ing the average 7 years of follow-up [21]. In a nationwide 
study performed by POLSCREEN in outpatient centers 
throughout the country (mean age for women 60.7 ± 
± 11.7; mean age for men 58 ± 11.6), 16% of men and 
7% of women reported in an interview MI and/or stroke. 
This high percentage of people with a history of CVEs in the 
cited study results from the analysis of only such persons 
who were registered by Primary Health Care for advice. The 
profile of the risk factors studied by this research group 
was also much more negative, with a large percentage of 
people treated for DM (16% of women and 15% men) and 
a large percentage of people with BMI ≥ 25 kg m2 [22].
In our study group, MS assessed by the three definitions 
increased risk of CVEs, but only in the case of MS according 
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to the NCEP-ATP III and IDF this relationship was statistically 
significant (HR 2.78; p < 0.001 and HR 2.39, p = 0.002 re-
spectively). In the Framingham Offspring Study a positive 
correlation between MS defined by NCEP-ATP III and CVEs 
was found [20]. Jeppesen et al. [19] found in a prospective 
study lasting over 9 years that MS by NCEP is an independent 
risk factor for CVEs. A Swedish prospective study assessed 
the three definitions of MS (NCEP, IDF and EGIR) in predicting 
CVEs. In this study, after taking into account age, gender, low-
-density lipoprotein and lifestyle, HR for CVEs was highest for 
MS according to the NCEP-ATP III (HR 1.59 95% confidence 
interval [CI] 1.25–2.03) [19]. In the prospective Strong Heart 
Study with patients with no identified diabetes, MS by WHO 
and NCEP-ATP III (but not by IDF) increased risk of CVEs. In 
patients with diabetes, MS by WHO seemed to be the most 
useful in assessing the risk of CVEs. The authors emphasize 
that the obtained data come from a population with a large 
proportion of people with obesity and diabetes [23]. Ahmadi 
et al. showed that MS (by NCEP) patients have significantly 
greater prevalence and severity as well as worse prognosis 
of coronary artery disease compared with patients with one 
component of metabolic syndrome [24]. Similar relationships 
showed Suh et al. During 8.1-year follow-up period MS (defini-
tion NCEP) was a significant risk factor for the development 
of cardiovascular disease although its impact varied between 
sexes [25]. Polish researchers who analyzed a population of 
more than 750 patients after ischemic stroke, found MS by 
NCEP in 54.3% of people, and after taking into account the 
criteria by the IDF 2005, in 60.8% of people. Both, the data 
available in the literature and our results demonstrate that 
the use of MS as defined by the NCEP and IDF can identify 
individuals at increased risk of CVEs. These people need 
to implement multi-primary prevention in order to prevent 
cardiovascular events [4].
Conclusions
1. The occurrence MS in the baseline study increases the 
risk of cardiovascular events in the follow-up study, as de-
fined by NCEP-ATP III 2001 and IDF 2005 almost 2.5-fold. 
2. In the urban Polish population it is necessary to identify 
persons with metabolic syndrome in order to select 
a group demanding the implementation of primary 
prevention of cardiovascular events.
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Table 4. Incidence and hazard ratio (HR) of cardiovascular events associated with presence of metabolic syndrome (MS)
MS present MS absent Incidence rate 
difference* 
(95%CI)
p HR 95%CI p**
No. of 
events per 
p-y at risk
Inciden-
ce rate#
No. of 
events per 
p-y at risk
Inciden-
ce rate#
Crude Adjusted*** Crude Adju-
sted***
WHO 10/879 11.4 36/6407 5.6 5.8  
(0.1–15.3)
0.043 2.04  
(1.003–4.13)
1.58  
(0.76–3.29)
0.049 0.22
NCEP 26/2223 11.7 20/5063 3.95 7.7  
(3.5–13.3)
< 0.001 2.96  
(1.65–5.31)
2.78  
(1.53–5.05)
< 0.001 < 0.001
IDF 30/3064 9.8 16/4222 3.8 6,0  
(2.2–10.4)
0.0014 2.57  
(1.4–4.72)
2.39  
(1.29–4.43)
0.002 0.006
*Incidence rate difference = absolute risk; **a p value of < 0.05 is considered statistically significant; ***adjusted to age, sex; #incidence rate per 1000 person-years; CI — confidence interval; p-y — person-
-years; WHO — World Health Organization; NCEP — National Cholesterol Education Program; IDF — International Diabetes Federation
Streszczenie
Wprowadzenie. Na całym świecie zwiększa się częstość występowania chorób cywilizacyjnych, w tym zaburzeń układu 
sercowo-naczyniowego, co sprawia, że działania profilaktyczne stają się coraz istotniejsze. Identyfikacja czynników 
ryzyka incydentów sercowo-naczyniowych (CVE) umożliwia określenie, które osoby wymagają wdrożenia skutecznej 
prewencji pierwotnej.
Celem badania była ocena częstości występowania zespołu metabolicznego (MS) w wielkomiejskiej populacji polskiej 
oraz związku między MS a ryzkiem wystąpienia CVE.
Materiał i metody. W badaniu przeanalizowano dane 798 osób. U wszystkich wykonano pomiary antropometryczne, 
ciśnienia tętniczego i badania laboratoryjne. Wszyscy uczestnicy badania wypełnili wystandaryzowany kwestionariusz 
dotyczący między innymi aktualnego stanu zdrowia, przebytych schorzeń oraz wywiadu rodzinnego w kierunku chorób 
układu sercowo-naczyniowego i cukrzycy.
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Wyniki. W badaniu wstępnym MS według Światowej Organizacji Zdrowia stwierdzono u 13,6%, według 3. Raportu 
National Cholesterol Education Program — Adult Treatment Panel (NCEP-ATP III) — u 32,7%, a według International 
Diabetes Federation (IDF) — u 43,7% osób. W badaniu kontrolnym CVE niezakończone zgonem stwierdzono u 5,8% 
osób. Płeć męska, wskaźnik masy ciała większy lub równy 25 kg/m2, otyłość brzuszna (oceniana za pomocą wskaźnika 
talia–biodra), stężenie glukozy w 120. min. doustnego testu tolerancji glukozy, stężenie cholesterolu frakcji lipoprotein 
o wysokiej gęstości oraz zespół metaboliczny według NCEP I IDF istotnie statystycznie obniżają ryzyko zawału serca (MI) 
i/lub udaru mózgu.
Wnioski. Biorąc pod uwagę potencjalne czynniki ryzyka CVE, cennym narzędziem w identyfikacji osób obciążonych 
ryzykiem wystąpienia MI i/lub udaru mózgu jest MS według NCEP-ATP III i IDF.
Słowa kluczowe: zespół metaboliczny, incydenty sercowo-naczyniowe, otyłość
Folia Cardiologica 2016; 11, 4: 261–267
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